Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05791604

The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics

Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. At present, there is no effective drugs and interventions to help control the appetite of PWS patients. More and more evidence has shown that gut microbiota is closely related to obesity. Probiotics and prebiotics can improve the structure of gut microbiota, thus improve blood lipid levels and other biochemical indicators of obese people. Therefore, this study intends to explore the effectiveness and safety of probiotics and prebiotics in controlling appetite and weight gain of PWS children.

Recruiting

Interested in participating?

Request Info

Key information

Age range

3 year–10 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Location status: Recruiting

Location contact

About this study

Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. Morbid obesity and related complications caused by hyperappetite are the most common causes of poor prognosis and death in PWS. At present, there is no effective drugs and interventions to help control the appetite of PWS patients. At present, more and more evidence has shown that gut microbiota is closely related to obesity. Probiotics and prebiotics can improve the structure of gut microbiota, thus improve blood lipid levels and other biochemical indicators of obese people. Therefore, this study intends to explore the effectiveness and safety of probiotics and prebiotics in controlling appetite and weight gain of PWS children. Participants will be divided into three groups, receiving probiotics, probiotics+probiotics or placebo treatment, and observe the changes in body weight, the structure of gut microbiota and metabolic level.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pre-adolescent children with Prader Willi syndrome which were definitely diagnosed by gene testing.
  • Consistent with the diagnostic criteria for obesity.
  • Not participate in other research projects at present or three months before the research;
  • Agree to participate in the test and obtain the consent of their parents; voluntarily be the subjects and sign the informed consent form.

Exclusion criteria

  • Losing weight in ways other than the intervention measures of this project, such as taking weight loss drugs or known drugs that cause weight change;
  • Use antibiotics within 1 month before the study and lasted for 3 days or more;
  • Use probiotics within 1 month before the study and lasted for 3 days or more;
  • Complicated with liver and renal insufficiency (alanine aminotransferase and serum creatinine indexes exceed 2 times the upper limit of the normal value set by the hospital);
  • Have gastrointestinal diseases affecting food digestion and absorption (such as severe diarrhea, constipation, severe gastrointestinal inflammation, active gastrointestinal ulcer, acute cholecystitis, etc.); severe diarrhea refers to watery stool 3 or more times a day and lasts for 3 or more days. severe constipation refers to defecation 2 or less times a week with difficulty in defecation;
  • Surgery was performed within 1 year before the study (except for appendicitis and hernia surgery);
  • Have hepatitis B, active tuberculosis, AIDS and other infectious diseases;
  • Those who are suffering from mental illness and are taking psychotropic drugs such as antidepressants.

Treatment and study plan

probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG

Dietary Supplement

Take probiotics, 2g each time, twice a day, for 12 weeks

Prebiotics with galactomannan and oligofructose

Dietary Supplement

Take probiotics, 2g each time, twice a day, for 12 weeks Take prebiotics, 25g each time, twice a day, for 12 weeks

Primary outcomes

  1. Body mass index

    Time frame: 12 weeks

    Body mass index is calculated as weight (kg)/[Height (m)^2]. Weight and height will be combined to report BMI in kg/m^2.

Secondary outcomes

  1. Body composition

    Time frame: 4 weeks and 12 weeks

    Body composition including body fat percentage will be measured through body composition meter.

  2. The structure of gut microbiota

    Time frame: 4 weeks and 12 weeks

    The 16s rRNA genes of fecal samples were analyzed.

  3. Height

    Time frame: 4 weeks and 12 weeks

    The height is accurate to 0.1cm.

  4. Weight

    Time frame: 4 weeks and 12 weeks

    The weight is accurate to 0.1kg.

  5. Waist circumference

    Time frame: 4 weeks and 12 weeks

    The waist circumference is accurate to 0.1cm.

  6. Glycosylated hemoglobin level

    Time frame: 4 weeks and 12 weeks

    The glycosylated hemoglobin is accurate to 0.1%.

  7. Fast triglyceride level

    Time frame: 4 weeks and 12 weeks

    The fast triglyceride level will be measured by IMMULITE 1000 (Siemens,Germany).

  8. Fast total cholesterol level

    Time frame: 4 weeks and 12 weeks

    The fast total cholesterol level will be measured by IMMULITE 1000 (Siemens,Germany).

  9. Fast low density lipoprotein level

    Time frame: 4 weeks and 12 weeks

    The fast low density lipoprotein level will be measured by IMMULITE 1000 (Siemens,Germany).

  10. Fast high density lipoprotein level

    Time frame: 4 weeks and 12 weeks

    The fast high density lipoprotein level will be measured by IMMULITE 1000 (Siemens,Germany).

  11. Defecation status

    Time frame: 4 weeks and 12 weeks

    Care givers describe the defecation status in the past 1 week, including the frequency, nature, and color.

  12. Abdominal pain

    Time frame: 4 weeks and 12 weeks

    Care givers describe whether abdominal pain occurs, and if so, provide frequency.

  13. Excessive flatulence

    Time frame: 4 weeks and 12 weeks

    Care givers describe whether excessive flatulence occurs, and if so, provide frequency.

  14. Fast insulin level

    Time frame: 4 weeks and 12 weeks

    The fast insulin level will be measured by IMMULITE 1000 (Siemens,Germany).

  15. Fast glucose level

    Time frame: 4 weeks and 12 weeks

    The fast glucose level is detected by fingertip blood with blood glucose meter.

  16. Body mass index

    Time frame: 4 weeks

    Body mass index is calculated as weight (kg)/[Height (m)^2]. Weight and height will be combined to report BMI in kg/m^2.

Study contacts

Contact information is provided by the study sponsor or research team.

Wei Lu, Dr

CONTACT

[email protected]

86-021-64933281

Sponsors and collaborators

Lead sponsor

Children's Hospital of Fudan University

Other

Registry information

Official study title

The Safety and Effectiveness Study of Prebiotics and Probiotics in the Intervention of Obesity in Children With Prader-Willi Syndrome

Important dates

Study start
2023
Primary completion
2028
Study completion
2029
First posted
Mar 30, 2023
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.